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Regulatory B cells restrict immune and inflammatory responses across a number of contexts.
This capacity is mediated primarily through the production of IL-10. Here we demonstrate
that the induction of a regulatory program in human B cells is dependent on a metabolic
priming event driven by cholesterol metabolism. Synthesis of the metabolic intermediate
geranylgeranyl pyrophosphate (GGPP) is required to specifically drive IL-10 production, and
to attenuate Th1 responses. Furthermore, GGPP-dependent protein modifications control
signaling through PI3Kδ-AKT-GSK3, which in turn promote BLIMP1-dependent IL-10 pro-
duction. Inherited gene mutations in cholesterol metabolism result in a severe autoin-
flammatory syndrome termed mevalonate kinase deficiency (MKD). Consistent with our
findings, B cells from MKD patients induce poor IL-10 responses and are functionally
impaired. Moreover, metabolic supplementation with GGPP is able to reverse this defect.
Collectively, our data define cholesterol metabolism as an integral metabolic pathway for the
optimal functioning of human IL-10 producing regulatory B cells.
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Immunosuppressive B cells form a critical component of theimmune regulatory compartment1,2. It is thought that theirsuppressive capacity derives mainly from their ability to pro-
duce IL-10, and in the absence of any lineage marker, this is
considered a hallmark of regulatory B cells3–6. Their functional
importance has been well described in mouse models of disease,
demonstrating a potent regulatory capacity across a number
of contexts including infection, cancer, and autoimmune
disease3,7–10. Comparable suppressive activity has been demon-
strated in human regulatory B cells in vitro, suggesting that these
cells also contribute toward regulating inflammatory responses in
humans5,6. In support of this, IL-10 producing B cells have been
demonstrated to be numerically depleted or functional impaired,
ex vivo, in patients with inflammatory disease5,11,12.
Despite the importance of IL-10 production by B cells, rela-
tively little is known about the molecular mechanisms that govern
its expression. Typically, induction of a regulatory phenotype in
both human and mouse B cells has been achieved through liga-
tion of TLR9 or CD405,6,13. Downstream, PI3K and ERK signals
appear to be important for IL-10 expression14,15. This is in broad
agreement with in vivo data from mouse models suggesting that
both TLR and CD40 signals are required for the induction of IL-
10 in response to inflammatory stimuli3,13. However, precise
details of the signaling cascades or cellular profiles underpinning
the induction of a regulatory program in B cells are poorly
understood.
Control of immune cell metabolism is critical in regulating
fundamental immunological processes16,17. However, in com-
parison to innate cell and T-cell lineages, there has been relatively
little work aimed at understanding the metabolic regulation of B-
cell biology18–20. Furthermore, there is currently no under-
standing toward the metabolic requirements of regulatory B cells.
An emerging concept from studies of regulatory T cells and M2
macrophages is their heightened reliance on lipid metabolism in
comparison to the metabolic requirements of inflammatory
immune cell lineages. Much of this work has focused on fatty acid
oxidation, defining this as a central pathway that underpins
polarization and effector functions in regulatory cells21. In con-
trast, the contribution of cholesterol metabolism (the multistep
conversion of HMG-CoA to cholesterol) to immune function is
less well characterized. Our recent studies, as well as those of
others, suggest that cholesterol metabolism plays a role in
restricting inflammatory responses22–24. These data are consistent
with patients carrying mutations in the pathway, who develop
severe and recurring autoinflammatory fevers, associated with
dysregulated B-cell responses, manifest by elevated serum
immunoglobulin levels25.
Given the immunoregulatory associations with cholesterol
metabolism, we set out to address its role in IL-10 producing B
cells. In doing so, we reveal that cholesterol metabolism is a
central metabolic pathway required for the induction of a reg-
ulatory phenotype in human B cells, and define the specific
metabolic intermediate of the pathway that mediates critical
signaling events for the induction of a regulatory B-cell program.
In vivo evidence for this specific metabolic requirement is pro-
vided by virtue of defective regulatory responses of B cells derived
from patients with inherited defects in cholesterol metabolism.
Results
Cholesterol metabolism drives regulatory B cell function.
Given that patients with dysregulated cholesterol metabolism
generate severe systemic inflammation and hyperactive B-cell
responses, we investigated the role of cholesterol metabolism in
regulatory B-cell function (the metabolic pathway is depicted in
Supplementary Fig. 1). Consistent with previous observations,
TLR9 ligation in human B cells induces a potent IL-10 response
(Fig. 1a, b, Supplementary Fig. 2a, b), which mediates their reg-
ulatory phenotype5,11. In agreement, TLR9 activated B cells were
able to suppress Th1 induction in CD4+ T cells in vitro (protocol
outlined in Fig. 1c). Neutralization of IL-10 resulted in a complete
loss of suppression, confirming the dependence on IL-10 in
mediating this function (Fig. 1d). In line with this, concentrations
of IL-10 produced by B cells upon TLR9 stimulation (>1 ng ml−1,
Fig. 1b) were sufficient to directly suppress CD4+ T cell IFNγ
expression (Supplementary Fig. 2c). In contrast, pre-treatment of
B cells with the HMG-CoA reductase inhibitor atorvastatin,
which inhibits an early step of the cholesterol metabolic pathway,
abrogated this suppressive capacity. Furthermore, supplementa-
tion of exogenous mevalonate reversed this defect, suggesting the
requirement for a specific metabolite downstream of HMG-CoA
(Fig. 1d).
The loss of suppressive capacity by IL-10 neutralization and
HMG-CoA reductase inhibition indicated that cholesterol
metabolism could be directly regulating IL-10 production.
Indeed, inhibition of HMG-CoA reductase impaired the ability
of B cells to produce IL-10, both at the mRNA and protein level
(Fig. 1e, f, Supplementary Fig. 3a, b). Once again, and consistent
with metabolic depletion downstream of HMG-CoA, exogenous
mevalonate was able to reverse this defect (Fig. 1e, f). In contrast
to IL-10, we observed a concurrent preservation in the
inflammatory response, as determined by TNF and IFNγ protein,
and IL6, and LTA gene expression (Fig. 1g, h, Supplementary
Fig. 3c, d). Together, these data indicated that cholesterol
metabolism was critical in mediating IL-10 expression, and
therefore the anti-inflammatory function of human B cells.
Cholesterol metabolism drives IL-10 independent of pheno-
type. We next aimed to understand how cholesterol metabolism
was able to mediate IL-10 production. Certain populations of
human B cells have been proposed as primary producers of IL-10.
The most well characterized of these are CD24hiCD27+ (B10)
and CD24hiCD38hi B cells5,6. In agreement with previous
observations, we observed that all populations measured (B10,
CD24hiCD38hi, naïve, memory, and plasmablast) contribute to
the pool of IL-10 expressing cells to varying degrees after sti-
mulation with CpG (IL-10+ cells ranging from 1 to 12% of B-cell
populations, Supplementary Fig. 4a, b). Furthermore, B10 and
CD24hiCD38hi B cells produced higher levels (two to threefold) of
IL-10 in response to TLR9 stimulation (Supplementary Fig. 4b).
Acquiring the capacity to produce IL-10 showed no dependence
on proliferation, as IL-10 production was seen irrespective of
proliferation state (Supplementary Fig. 4c). Following inhibition
of HMG-CoA reductase we observed no change in frequencies of
B cell populations, viability, or cell surface markers (HLA-DR,
CD86, or CD40), excluding the possibility that perturbation of
cholesterol metabolism was depleting specific B-cell subsets that
possess a greater propensity to express IL-10 (Supplementary
Fig. 4d–f). Furthermore, HMG-CoA reductase inhibition resulted
in a 2–3-fold reduction in IL-10 expression irrespective of B-cell
population (either naïve, memory, B10, or CD24hiCD38hi, Sup-
plementary Fig. 4g). Therefore, these data indicated a role for
cholesterol metabolism in regulating IL-10 production that is
shared across B-cell populations, rather than an effect on specific
populations.
Cholesterol metabolism drives IL-10 via GGPP. To more pre-
cisely understand the mechanistic control by cholesterol meta-
bolism, we next sought to investigate if a specific pathway
metabolite downstream of HMG-CoA was regulating IL-10.
Cholesterol metabolism encompasses a number of metabolic
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pathways implicated in immune function including mevalonate,
isoprenyl and sterol metabolism (Supplementary Fig. 1), all of
which are attenuated by HMG-CoA reductase inhibition to
varying degrees. Given that defects in the isoprenyl branch have
been demonstrated to result in hyperinflammatory responses
in vivo23,26, we investigated if isoprenylation was regulating IL-
10. To this end, we targeted geranylgeranyltransferase (GGTase)
and farnesyltransferase (FTase), enzymes known to post-
translationally modify proteins with geranylgeranyl pyropho-
sphate (GGPP) or farnesyl pyrophosphate (FPP) groups respec-
tively (enzymes and metabolites outlined in Fig. 2a). Inhibition of
GGTase, but not FTase, substantially reduced TLR9-induced IL-
10 production, indicating that geranylgeranyl dependent mod-
ifications regulate IL-10 expression (Fig. 2b, Supplementary
Fig. 5a, b). In keeping with the effects of HMG-CoA reductase
inhibition, inflammatory cytokine production was preserved
(Fig. 2c). Furthermore, we observed no or little effect on the
proliferation, differentiation, and antibody production by B cells
after TLR9 ligation in the presence of either atorvastatin or GGTi
during longer cultures (5–7 days, Supplementary Fig. 5c). In
experiments to test GGTase specificity, we also observed that IL-









































































Fig. 1 Cholesterol metabolism drives regulatory B cell function. a, b Kinetics of IL10mRNA transcript (a) and IL-10-secreted protein (b) expression at various
time points in human B cells after TLR9 stimulation (n= 4 for mRNA or n= 4–5 for protein). IL10mRNA was measured by qRT-PCR, and calculated relative to
18S. c Schematic protocol for the co-culture for T and B cells. Briefly, human B cells were stimulated through TLR9 ± atorvastatin (AT) ±mevalonate (MA)
overnight, before washing and addition to anti-CD3/28 stimulated human CD4+ T cells for 4 days ± αIL-10 antibody. d IFNγ production in human CD4+ T cells
after co-culture with autologous TLR9-activated B cells (n= 6, pval=0.03 and 0.02). IFNγ suppression was calculated by ((x− y)/x)*100 where x= IFNγ
production by T cells alone, y= IFNγ production in co-cultured T cells. e IL-10 expression in human B cells after stimulation through TLR9 ± AT ±MA (n= 7,
pval=0.003). f IL-10 mRNA expression over time in human B cells after stimulation through TLR9 ±AT±MA (n= 4). g TNF expression in human B cells after
stimulation through TLR9 ±AT ±MA (n= 7). h IL6 or LTAmRNA expression, relative to 18S, in human B cells after stimulation through TLR9 ±AT (n= 4). Each
data point represents individual donors. All data presented are mean ± SD. Statistical testing in all figures was done by a Friedman’s test with Dunns’s multiple
comparisons test, or for (f) a mixed-effects model with Dunnett’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, and all significant values
are shown.
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of GGTase-II upon TLR9 ligation did not affect IL-10 expression
(Supplementary Fig. 5d).
To support the notion of GGPP dependency, we depleted
metabolites within the pathway with atorvastatin, and found that
specifically supplementing the geranyl branch with exogenous
GGPP prevented the blockade of IL-10 production (Fig. 2d,
Supplementary Fig. 5e). In agreement with a specific effect of
GGPP, supplementation with squalene—a metabolite down-
stream of the isoprenylation branch—was unable to rescue IL-
10 production (Supplementary Fig. 5f). Finally, to understand if
cellular utilization of GGPP was dependent on the enzymatic
activity of GGTase, we supplied cells with exogenous GGPP
together with inhibition of GGTase. We found that GGPP was
unable to rescue levels of IL-10 (Fig. 2e), consistent with the idea
that both GGTase activity and GGPP sufficiency are required for
TLR9 induced expression of IL-10.
GGPP regulates signaling through TLR9. The most well char-
acterized targets of isoprenylation are Ras superfamily pro-
teins27,28. Ras-dependent pathways downstream of TLR9 include
Raf-MEK-ERK and PI3K-AKT cascades (Fig. 3a). Signaling
through both pathways is critically required for IL-10 production,
as inhibition of either pathway is sufficient to block TLR9-
dependent IL-10 induction (Fig. 3b, c). Therefore, we sought to
address if activation of these pathways is dependent on GGPP.
Following GGTase inhibition, AKT phosphorylation on Ser473
was severely impaired, whereas ERK phosphorylation was mod-
estly reduced at early timepoints (Fig. 3d, quantification shown in
Supplementary Fig. 6a, b). Downstream, AKT restricts GSK3
activity through an inhibitory phosphorylation event targeting
Ser929. In keeping with the idea that GSK3 suppression is
required for IL-10 production, chemical inhibition of GSK3
enhanced TLR9-induced IL-10 expression (Fig. 3e). Blocking
GGTase activity resulted in reduced Ser9 phosphorylation on
GSK3. This indicated preserved activation of GSK3, and that
GGTase activity negatively regulates GSK3, which in turn is
necessary for IL-10 production (Fig. 3f). We then examined if
inhibition of GSK3 was sufficient to rescue an upstream pertur-
bation of geranylgeranylation. Indeed, bypassing GGTase through
GSK3 inhibition was able to fully rescue IL-10 expression, with-
out affecting TNF (Fig. 3g, Supplementary Fig. 6c). Together
these data suggest that following TLR9 engagement, IL-10
induction through AKT-GSK3, and possibly ERK, is dependent
on GGTase activity.
PI3Kδ regulates IL-10 expression in human and mouse B cells.
We next aimed to determine how geranylgeranyl-driven phos-
phorylation cascades regulate AKT-GSK3 signaling. PI3K med-
iates Ras-dependent AKT signaling, which suggests that
isoprenylation-driven phosphorylation cascades through AKT
are dependent on PI3K activity. Accordingly, pan inhibition of
PI3K blocked expression of IL-10 upon TLR9 stimulation
(Fig. 4a). We found, by selective inhibition of either δ, α, or γ
isoforms of PI3K, that IL-10 is primarily regulated through PI3Kδ
downstream of TLR9 (Fig. 4b). To further support the impor-
tance of PI3Kδ, we examined IL-10 production in splenic B cells
derived from mice expressing either a hyperactive (E1020K) or
catalytically inactive (D910A) PI3Kδ subunit. Following TLR9
activation, presence of the hyperactive PI3Kδ mutant resulted in
threefold increased expression of IL-10, whereas the catalytically
inactive PI3Kδ resulted in almost a complete loss of IL-10 pro-
duction (Fig. 4c). Furthermore, and in agreement with our pre-
vious observations, TNF production was preserved (Fig. 4c).
These data suggest that isoprenylation-dependent interactions
between Ras and PI3Kδ are required for IL-10 production, and
likely underpin the regulatory function of B cells.
GGPP regulates IL-10 induction via BLIMP1. Currently there is
no defined transcription factor that regulates IL-10 in human B
cells. Therefore, we sought to understand how IL-10 is tran-
scriptionally regulated, and to clarify the role for GGPP in this
process. Stimulation of B cells in the presence of actinomycin D
indicated that a transcriptional event within the first 24 h was
necessary for IL-10 production (Supplementary Fig. 7a). There-
fore, we suspected that under conditions of GGTase inhibition,
expression of a transcription factor necessary for IL-10 may be
compromised. To test this, we performed RNA-sequencing on









































































































































Fig. 2 Cholesterol metabolism drives IL-10 via GGPP. a Schematic diagram showing key metabolites and enzymes of the isoprenylation route in
cholesterol metabolism. b, c IL-10 (b) and TNF (c) expression in human B cells after stimulation through TLR9 ± geranylgeranyl transferase inhibition
(GGTi, GGTi-298) ± farnesyl transferase inhibition (FTi, FTi-277) (n= 5 for IL-10, pval = 0.001; n= 6 for TNF). d IL-10 expression in human B cells after
stimulation through TLR9 ± atorvastatin (AT) ± geranylgeranyl pyrophosphate (GGPP) (n= 4, pval= 0.009). e IL-10 expression in human B cells after
stimulation through TLR9 ± GGTi ± GGPP (n= 4, pval both 0.03). Each data point represents individual donors. All data presented are mean ± SD.
Statistical testing in all figures was done by a Friedman’s test with Dunns’s multiple comparisons test. *P < 0.05, **P < 0.01, and all significant values
are shown.
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GGTase inhibition. Principal component analysis demonstrated
that the main variation in the transcriptional profile of the cells
was dependent on GGTase activity, as expected (Fig. 5a, Sup-
plementary Fig. 7b). We then interrogated the list of differentially
expressed genes (±1.5-fold, false-discovery rate (FDR) < 0.05) for
those known or likely to encode human transcription factors (as
defined by ref. 30). Among the 73 differentially expressed tran-
scription factors, 9 have been shown to regulate IL-10 expression
in other cell types (Fig. 5b–d, Supplementary Fig. 7c), either
through activation or repression (defined in ref. 31). We decided
to focus on BLIMP1 for two reasons. First, its transcript is enri-
ched in IL-10+ human B cells32. Secondly, interrogation of a
mouse B cell ChIP- and RNA-seq data set33 demonstrated that
binding of BLIMP1 to the Il10 locus correlates with increased IL-
10 expression (Supplementary Fig. 7d). We first confirmed
reduced expression of BLIMP1 protein upon GGTase inhibition
(Supplementary Fig. 7e), and consistent with previous data, we
observed increased expression of BLIMP1 protein within the IL-
10+ B cell population (Fig. 5e). To more thoroughly address its
role, we performed gene targeting experiments on BLIMP1 in
primary human B cells. TLR9 stimulation strongly upregulated
BLIMP1 expression in multiple B-cell populations, including,
unexpectedly, recently activated naïve and CD24hiCD38hi B cells
(Fig. 5f, Supplementary Fig. 7f, g), while siRNA knockdown was
able to reduce TLR9-dependent protein level expression by ~60%
(Fig. 5g, h). In agreement with a central role in regulating IL-10,
siRNA-mediated knockdown of BLIMP1 reduced IL-10 expres-
sion by 50–90%, whereas TNF production was preserved (Fig. 5i).
Together, these data demonstrate that BLIMP1 regulates IL-10 in
human B cells, and its expression is dependent on cholesterol
metabolism for its provision of GGPP.
MKD patients generate poor regulatory B-cell responses. Our
data demonstrated that cholesterol metabolism is essential for B
cell derived IL-10 production. We therefore sought to validate our
findings in the context of human inflammatory disease. To
address this, we studied MKD patients, who carry a partial loss-
of-function mutation in the mevalonate kinase gene, whose
cognate substrate lies directly downstream of HMG-CoA in the
metabolic pathway (highlighted in Supplementary Fig. 1a). These
patients present with a complex and severe autoinflammatory
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Fig. 3 GGPP regulates signaling through TLR9. a Schematic of Ras-dependent signaling cascades downstream of TLR9. b, c IL-10 expression in
human B cells stimulated through TLR9 ± inhibition of (b) AKT (AKTi, MK-2206) or (c) ERK (ERKi, SCH772984) (n= 4, pval= 0.005, and 0.001).
d Phosphorylation of AKT (ser473) or ERK1/2 (Thr202/Tyr204) over time in human B cells upon stimulation through TLR9± inhibition of geranylgeranyl
transferase (GGTi) (representative of n= 3). e IL-10 expression in human B cells stimulated through TLR9± inhibition of GSK3 (GSK3i, CHIR-99021)
(n= 9, pval < 0.001). f Phosphorylation of GSK3 (ser9) over time in human B cells upon stimulation through TLR9± inhibition of geranylgeranyl transferase
(GGTi-298), relative to unstimulated controls (n= 4, pval= 0.02). g IL-10 and TNF expression in human B cells stimulation through TLR9 ± GGTi ± GSK3i
(n= 7, pval= 0.0001). Each data point represents individual donors. All data presented are mean ± SD. Statistical testing in figures in (b), (c), and (e) was
done by a paired t test, f using a twoway ANOVA with Sidak’s multiple comparisons test, and g by Friedman’s test with Dunns’s multiple comparisons test
**P < 0.01, ***P < 0.001, ****P < 0.0001 and all significant values are shown.
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MKD patients to age and sex matched healthy controls (Patient
information in Supplementary Fig. 8a). We observed similar
frequencies of B10 cells, whereas CD24hiCD38hi B cells were
reduced (Fig. 6a, b). This is in line with a general shift from a
naïve to memory like B cell phenotype in MKD patients (Sup-
plementary Fig. 8b). In longer term in vitro cultures, we observed
that B cells from MKD patients possess a normal capacity to
proliferate, differentiate, and to produce antibodies (Supplemen-
tary Fig. 8c).
We next examined if dysregulated cholesterol metabolism in
patients with MKD leads to an inability to mount an IL-10
response, which could contribute to disease persistence or
exacerbation. In line with this hypothesis, MKD patients
generated poor IL-10 responses after stimulation through TLR9
(30–70% reduction versus controls, Fig. 6c), while TNF expres-
sion was enhanced in 2 of 4 donors (Supplementary Fig. 8d).
Interestingly, the defect in IL-10 production could be reversed by
the addition of GGPP, indicating that at least in part, this defect
was due to a relative deficiency of the isoprenyl metabolite
(Fig. 6c). As with our previous observations, IL-10 expression was
reduced across all B-cell phenotypes, including an approximately
threefold reduction within B10 and CD24hiCD38hi B cells
(Fig. 6d, gating in Supplementary Fig. 4a, d).
We previously identified GSK3 as a key node in IL-10
production (Fig. 3e–g). Therefore, we addressed if reduced IL-
10 levels in MKD patients could be rescued through inhibition of
GSK3, which would provide a rescue to signaling pathways
further downstream of GGPP supplementation. Indeed, GSK3
restriction in MKD patients was able to fully rescue IL-10
production (Fig. 6e). As with our previous data, supplementation
with squalene was unable to restore IL-10 expression in MKD
patients, supporting evidence that the IL-10 defect is specifically
due to poor GGPP production (Supplementary Fig. 8e). To
examine the dependency of IL-10 expression on BLIMP1 in MKD
patients, given our previous findings in healthy donor B cells, we
analyzed the capacity of MKD patients to upregulate BLIMP1 in
response to TLR9 stimulation. In spite of the increased
proportions of memory B cells present in MKD patients, we
demonstrated a reduced capacity to induce BLIMP1 compared to
healthy B cells in 2 of 2 donors (Fig. 6f), providing additional
mechanistic data to explain why these patients show reduced B
cell derived IL-10.
We then addressed if the defect in IL-10 production from MKD
patients was associated with a functional impairment. Indeed, we
observed that MKD B cells were unable to suppress IFNγ
production by autologous CD4+ T cells, when compared to B cells
from healthy controls (Fig. 6g). Moreover, pre-treatment of MKD B
cells with exogenous GGPP prior to co-culture, was able to restore
regulatory capacity in 2 of 2 donors tested (Supplementary Fig. 8f),
suggesting that a GGPP deficiency in MKD patients impairs both
IL-10 expression and results in defective suppressive function.
Given our B-cell phenotype, we examined whether MKD imposed
more a systemic defect on IL-10 producing immune cells we
investigated whether T-cell responses from MKD patients were also
defective in IL-10 expression. In contrast to B cells, T cells were able
to induce effective IL-10 responses, alongside comparable levels of
other cytokines, including TNF, IFNγ, IL-2, and IL-17 (Supple-
mentary Fig. 8g).
Finally, to corroborate our results, we interrogated an indepen-
dent dataset (GSE43553 taken from ref. 34) that performed global
gene expression analysis in PBMCs ex vivo, derived from healthy
controls (n= 20) and MKD patients (n= 8). Gene set enrichment
analysis identified defective Ras (KRAS) and PI3K-Akt-mTOR
signaling pathways in MKD patients when compared to healthy
donors, in line with our own observations (Fig. 6h). Collectively,
and consistent with our in vitro findings, these data suggest that
dysregulated cholesterol metabolism in vivo, as seen in MKD
patients, results in impaired regulatory B-cell responses.
a b
c














IC50 = 0.4 pM
Nemiralisib ( )
–6 –4 –2 0 2 4
log (concentration) nM
IC50 = 36 nM
HS-173 ( )
–6 –4 –2 0 2 4
log (concentration) nM





















































































104 105103–103 0 104 105103–103 0 104 105103–103 0
Fig. 4 PI3Kδ regulates IL-10 expression in human and mouse B cells. a IL-10 expression in human B cells stimulated through TLR9± pan inhibition of PI3K
(PI3Ki, ZSTK474) (n= 4, pval= 0.008). b IL-10 expression in human B cells stimulated through TLR9± inhibitors for specific family members of PI3K:
these being δ (Nemiralisib), γ (IP-549), or α (HS-173), over a range of concentrations (n= 4). c IL-10 and TNF expression in mouse B cells after stimulation
through TLR9. Mice used were wild type (WT), hyperactive PI3Kδ (E1020K), or catalytically inactive PI3Kδ (D910A) (n= 3, pval= 0.002 and <0.0001).
Each data point represents individual donors or mice. Data presented are mean ± SD. Statistical testing in figures in a was done by a paired t test, or in c by
a one-way ANOVA with Dunnet’s multiple comparisons test. **P < 0.01, ****P < 0.0001 and all significant values are shown.
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Discussion
This study provides the first description of the metabolic
requirements for IL-10 producing B cells, arguing for a central
reliance on cholesterol metabolism. Our data point to a model in
which synthesis of GGPP prior to stimulation permits trans-
duction of receptor signaling cascades necessary for IL-10
expression. As a consequence, the transcription factor BLIMP1
is induced, which then promotes IL-10 gene expression. We
propose that this has direct relevance in vivo, as IL-10 producing
B cells from patients who carry mutations in the cholesterol
metabolic pathway phenocopy our in vitro findings (outlined in
Fig. 7).
Investigations into B-cell metabolism have focused primarily
on either antibody production or activation induced metabolic
reprogramming18–20,35. As alluded to above, there was no
understanding of the metabolic requirements for regulatory B
cells. Here, we demonstrate that cholesterol metabolism is critical
in mediating the regulatory capacity of human B cells through its
control of IL-10. We have also previously shown that T cells
require an intact cholesterol biosynthesis pathway to switch from
inflammatory Th1 cells (IFNγ+IL-10−) to IFNγ+IL-10+ cells22,
although this appears to be regulated by an alternative mechan-
ism, as inhibition of isoprenylation did not affect this switch.
Interestingly, cholesterol metabolism has been implicated in
regulatory T-cell function through a mechanism dependent on
ICOS and CTLA-4, while having no effect on IL-10 expression36.
Although the authors did not explore this, we anticipate that
regulatory T cells may also possess significant GGPP dependency,
as regulatory T-cell function is especially reliant on PI3Kδ
activity37. Therefore, while cholesterol metabolism appears to
regulate different effector molecules between the cell types, it may
be that regulatory T and B cells rely more heavily on cholesterol
metabolism due to the necessity for potent GGPP-dependent
PI3Kδ activity.
Much of the experimental data regarding immunity and meta-
bolism have suggested a paradigm in which the integration of
metabolic pathways controlling cell fate arises as a direct con-
sequence of immune cell activation. Based on the ability of cho-
lesterol metabolism to control induction of a regulatory program in
human B cells by modulating TLR9 signaling, we propose that the
programming of immune responses through cholesterol metabolism
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Fig. 5 GGPP regulates IL-10 induction via BLIMP1. a Principal component analysis of human B cells after stimulation through TLR9 ± geranylgeranyl
transferase inhibition (GGTi), with analysis performed on total normalized counts generated from RNA-sequencing data, before statistical analysis (n= 7).
b Workflow for the identification of putative IL-10 transcription factors. First, differentially expressed genes were cross referenced with known or likely
human transcription factors, and the subsequently identified differentially expressed transcription factors were cross referenced with previously validated
IL-10 transcription factors in either macrophages or T cells. Differentially regulated IL-10 transcription factors are shown in (c) and all differentially
regulated transcription factors are shown in (d) (n= 7). e Expression of BLIMP1 in human B cells within either IL-10+ or IL-10− B cells after stimulation
through TLR9 (n= 6, pval= 0.003). f Western blot showing BLIMP1 expression in human B cells either in unstimulated or stimulated through TLR9 (CpG)
after 40 h (representative of three independent experiments). g, h Western blot showing expression of BLIMP1 in human B cells after stimulation of TLR9
and nucleofection with either a scrambled control (Scr) or BLIMP1 siRNA (n= 5, pval= 0.001). i IL-10 and TNF expression in human B cells stimulated
through TLR9 after nucleofection with either Scr or BLIMP1 siRNA (n= 6 for flow cytometry, pval= 0.002; and 5 for ELISA, pval= 0.009). Each data point
represents individual donors. All data presented are mean ± SD where average values are shown. Statistical analysis in all figures was done using a paired
t test. **P < 0.01, ***P < 0.001 and all significant values are shown.
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constitute a metabolic preprogramming event. This preprogram-
ming requires the generation of GGPP prior to cellular stimulation
(rather than upon or as a direct consequence of stimulation), that
has the effect of fine-tuning signaling cascades. This notion of
preprogramming is consistent with data showing the GGPP-
dependent constitutive localization of Ras family proteins at the
cell membrane and endosomes, and that blockade of cholesterol
metabolism retains Ras in the cytoplasm38,39. In other words, the
state of signaling intermediates is preset by the state of cholesterol
metabolism of the quiescent cell at any given point.
Our finding that either GGPP deficiency or inhibition of its
cognate enzyme GGTase was sufficient to block IL-10 production
suggested that both the metabolite and its enzyme are absolutely
required for the induction of a regulatory phenotype. Notably,
inhibition of FTase was unable to inhibit IL-10 production, likely
due to the differing targets for geranylgeranylation and farnesy-
lation27. This suggests that cholesterol metabolism drives the
anti-inflammatory function of B cells primarily through the
synthesis of the isoprenyl group GGPP. These observations
contrast with previous reports suggesting that isoprenylation
largely mediates the restriction of pro-inflammatory cytokines,
including TNF, IL-6, and IL-1β. It should be noted however, that
these data were derived from studies of mouse macrophages and
intestinal epithelial cells23,40,41. Nonetheless, while human B cells
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Fig. 6 MKD patients generate weak regulatory B-cell responses. a, b Frequencies of B10 (CD24hiCD27+) and CD24hiCD38hi regulatory B cells in
mevalonate kinase deficient (MKD) patients, compared to age and sex matched healthy donors (HD). c IL-10 expression in MKD patients and HD after
stimulation through TLR9 ± geranylgeranyl pyrophosphate (GGPP). d IL-10 expression within B10, CD24hiCD38hi, naïve, and memory populations, showing
the differential contribution of B cell phenotypes to IL-10 production (n= 3, pval= <0.0001, 0.002, and 0.01). e IL-10 expression in MKD patients and HD
after stimulation through TLR9 ± GSK3i (CHIR-99021). f BLIMP1 expression in naïve and memory HD or MKD patient B cells after stimulation through
TLR9 (n= 2). g IFNγ production in human CD4+ T cells of healthy controls and MKD patients after co-culture with autologous TLR9-activated B cells.
Protocol is outlined in Fig. 1c. h Gene set enrichment analysis conducted on gene expression profiles from an independent dataset (GSE43553) on PBMCs
ex vivo in MKD patients (n= 8) or HD (n= 20). Heatmap shows all genes involved in “Hallmark” PI3K-Akt-mTOR gene set collection from MSigDB, and
their relative expression in MKD vs. HD. Enrichment plots show PI3K-Akt-mTOR and KRAS DN (genes downregulated by KRAS activation) in MKD vs. HD.
Each data point represents individual donors. All data presented are mean ± SD where average values are shown. Statistical analysis in (d) was conducted
using a paired t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 and all significant values are shown.
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are known to co-express inflammatory cytokines TNF and IL-6
alongside IL-1042, we saw no alteration in their capability to
produce these upon blockade of GGTase. This suggests that pro-
inflammatory cytokine production relies less heavily on choles-
terol metabolism. Our finding that cholesterol metabolism reg-
ulates PI3K signaling may somewhat explain this, given that PI3K
can differentially regulate pro- vs. anti-inflammatory cytokine
production upon TLR ligation43–45.
We found that the mechanistic control of cholesterol meta-
bolism revolves around its ability to regulate PI3Kδ-AKT sig-
naling downstream of TLR9, although this is likely not the only
target as we also saw an effect on pERK activation. Although we
documented expression of all isoforms of PI3K, we observed that
PI3Kδ, to a greater extent than PI3Kα or PI3Kγ, contributed to
IL-10 expression in human B cells upon TLR9 ligation. This
finding is consistent with a recent observation identifying IL-10
producing B cells as the primary pathological cell type in a model
of activated PI3Kδ syndrome, driving Streptococcus pneumoniae
persistence14. We further suggest that GSK3 inactivation down-
stream of GGPP-dependent PI3Kδ-AKT signaling is also required
for optimal IL-10 expression. Consistent with this, AKT-driven
phosphorylation of GSK3 on Ser9 is known to differentially
regulate cytokine production in monocytes29. Moreover, we
observed that reduced IL-10 expression induced in the context of
defective isoprenylation could be rescued through inhibition of
GSK3. In line with our findings, GSK3 inhibition in both innate
cells29 and Th1/2/17 cells46 potentiates IL-10 expression. This
provides a common framework in all immune cells, whereby
restriction of GSK3 activity upon receptor ligation is necessary for
IL-10 expression.
Downstream of TLR9 ligation, BLIMP1 was shown to posi-
tively regulate IL-10 expression, suggesting its role as a tran-
scriptional regulator of IL-10 in human B cells. Indeed, BLIMP1
has been previously demonstrated to control IL-10 induction in
T cells47, and in a recent study in regulatory B cells48. Analysis
of publicly available ChIP-seq datasets in both mouse and
human B cells are in line with this finding, suggesting that IL-10
is a significantly enriched target of BLIMP133,49. This observa-
tion is reminiscent of recent work highlighting the role for
BLIMP1-expressing regulatory plasmablasts and plasma cells
in vivo3,4,50,51, but also in humans ex vivo51. While this previous
work provided a correlative link between BLIMP1 and IL-10, we
suggest that BLIMP1 is a direct regulator of IL-10 in B cells.
Therefore, it will be interesting in future work to further
delineate a direct link and understand if there is a common
mechanism regulating B cell derived IL-10 in both mouse and
human B cells. Surprisingly, we observed expression of BLIMP1
in recently activated IgD+CD27− (naïve) B cells upon
TLR9 stimulation (Supplementary Fig. 7F). This has also been
observed previously, where expression of BLIMP1 alongside a
conformationally open chromatin arrangement in naïve B cells
has been demonstrated52. This raises the question of whether
BLIMP1 plays an earlier role in B-cell function at much earlier
stages of activation, distinct from its more classical function
linked to the development of terminally differentiated B cells. In
addition to BLIMP1, several interesting candidates such as AHR
and BATF were also identified in our screen, which warrant
further investigation.
To validate our findings in the context of human disease, we
investigated patients with dysregulated cholesterol metabolism.
MKD patients carry a mutation in the mevalonate kinase gene. As
a consequence, their ability to convert mevalonate to mevalonate-
5-phosphate is severely impaired. In keeping with our findings
following perturbation of cholesterol metabolism in healthy B
cells in vitro, we observed poor regulatory responses in B cell
from these patients. This anti-inflammatory defect uncovered an
unappreciated dimension to the spectrum of MKD. This included
a reduced ability to produce IL-10, associated with a functional
impairment in restricting T-cell responses. In both cases, sup-
plementation of GGPP was able to reverse this defect, suggesting
that a lack of metabolic flux through the pathway might be
contributing. Interestingly, GSK3 inhibition was also able to
reverse the reduced IL-10 production observed in MKD patients,
providing a specific signaling node downstream of GGPP defi-
ciency that is dysregulated in patients. In agreement with GGPP
deficiency, MKD patients have been demonstrated to accumulate
unprenylated Ras proteins53. Further characterization of MKD B
cells demonstrated that, despite their increased frequencies of
memory B cells, these cells do not effectively induce BLIMP1
expression in response to TLR9. This data is in line with our
observations demonstrating that a deficiency in geranylger-
anylation results in an inability to properly induce BLIMP1
expression.
To date, the causative factor driving disease pathology has been
defined as excessive inflammatory cytokine production, driven
through increased macrophage driven IL-1β production23,54, but
also through the induction of a trained immunity phenotype
driven by accumulated mevalonate55. Here, we also provide evi-
dence that CD4+ T cells in MKD patients induce cytokine
responses equivalent to those in healthy donors, suggesting this
effect is intrinsic to B cells. Given the role of regulatory B cells in
restricting cellular responses, we propose this B cell defect could
contribute to the relapsing and remitting nature of the disease.
Moreover, it has been shown that B cell-derived IL-10 is
important in T follicular helper organization, and restricting
excessive antibody responses via interaction with Tfh cells56,57. It
is therefore tempting to speculate that these patients generate
inappropriately inflammatory B-cell responses in lymphoid
organs. This would go some way to explain the clinical obser-
vations in MKD patients who are typically diagnosed in early
childhood with high circulating IgD and IgA levels25.
In summary, these results argue that cholesterol metabolism
acts as a central metabolic pathway promoting an intrinsic
anti-inflammatory program in B cells, driving IL-10 production








Fig. 7 B cell IL-10 regulation by GGPP. IL-10 production by B cells is
regulated by cholesterol metabolism though geranylgeranyl pyrophosphate,
controlling signaling cascades and BLIMP1 induction downstream of TLR9
engagement. MKD mevalonate kinase deficiency.
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Methods
Cell isolation and culture. Blood samples were obtained locally from healthy
donors, and mevalonate kinase deficient patients were recruited from Royal Free
Hospital NHS Foundation Trust. Human: Peripheral blood mononuclear cells were
isolated by density gradient centrifugation using Lymphoprep (Alere Technolo-
gies). Fresh CD19+ B cells and CD4+ T cells were subsequently isolated by
magnetic cell sorting, based on CD19- and CD4-positive or CD4-negative selection
(MACS, Miltenyi Biotech); purity was consistently >97%. Cells were cultured in
RPMI-1640 (Sigma), 10% Fetal Bovine Serum (Sigma) with 2 mM L-glutamine
(Sigma), 0.1 g L−1 sodium bicarbonate (Sigma), supplemented with 100 UmL−1
penicillin and 0.1 mgmL−1 Streptomycin (PAA), and 10 mM Hepes (PAA), in
round bottom 96-well Nunclon plates (Thermo Scientific) at 0.3 × 106 cells/well.
B cells were activated with TLR9 ligand CpG ODN 2006 (1 μM, Invivogen),
alongside recombinant human IL-2 (25 Uml−1, Proleukin, Novartis) typically for
40 h, or as indicated. Where indicated, CellTrace Violet (Thermofisher Scientific)
labeling of cells was conducted as per manufacturer’s instructions, used at a final
concentration of 2 μM prior to stimulation. All inhibitors and metabolites were
extensively titrated prior to use, and reagent details are as follows: MK-2206 (Akt,
100 nM), FTi-277 (Farnesyl transferase, 5 μM), GGTi-298 or GGTi-2133 (Ger-
anylgeranyl transferase-II, 5 μM), Psoromic acid (Geranylgeranyl transferase-I,
0.1–10 μM) CHIR-99021 (GSK3α/β, 5 μM), atorvastatin (HMG-CoA reductase,
5 μM), SCH772984 (ERK, 1 μM), HS-173 (p110α, 1 pM–1 μM), IP-549 (p110α,
1 pM-1 μM), nemiralisib (p110δ, 1 pM–1 μM), (R)-mevalonic acid (250 μM),
Squalene (1–10 μM), and geranylgeranyl pyrophosphate (2 μM). Mouse: Total
splenocytes were isolated from 8–15-week-old mice, red blood cells were lysed
(Biolegend), and resulting single cell suspensions were cultured in the above media
in flat bottom 48-well Nunclon plates (ThermoFisher), at 1 × 106 cells/well. Wild
type, p110δ E1020K and p110δ D910A mice used in the study have been described
previously58. B cells were stimulated with CpG ODN 1826 (1 μM, Invivogen) in the
presence of IL-2 (25 Uml−1, Proleukin, Novartis) for 48 h. Other ligands used for
stimulation include: CD40L (6245-CL, 1 μg ml−1, R&D Systems), LPS (10–500 ng
ml−1, Invivogen), and IFNα (200–1000 Uml−1).
T- and B-cell coculture. Autologous CD4+ T and CD19+ B cells were isolated
from healthy donors or MKD patients as described above. B cells were incubated
overnight with CpG (1 μM), IL-2 (25 Uml−1), ±atorvastatin, ±mevalonic acid. In
parallel, CD4+ T cells were stimulated with plate bound αCD3 and αCD28 (both
1 μg ml−1, Biolegend). After 12 h, B cells were washed twice, added to the T cells at
a 1:1 ratio, and cultured for 4 days ± αIL10 antibody ± isotype control (5 μg ml−1,
both Biolegend). Assessment of the direct effect of IL-10 on human CD4 T cells
was performed by plate bound αCD3/28 (1 μg ml−1) stimulated, cell trace violet
labeled T cells, alongside incubation of the indicated concentration of IL-10 for
4 days.
Flow cytometry. Antibodies used were as follows: IL-10-PE (dilution 1:800, JES3-
19F1), TNF-BV421 (dilution 1:400, Mab11), IFNγ-PE/Cy7 (dilution 1:400, 4S.B3),
CD20-AF647 (dilution 1:400, 2H7), CD24-BV605 (dilution 1:400, ML5), CD27-
FITC (dilution 1:200, M-T271), CD38-PE/Cy7 (dilution 1:400, HB-7), IgD-BV421
(dilution 1:400, IA6-2), CD4-FITC (dilution 1:200, A161A1), HLA-DR-PerCP/
Cy5.5 (dilution 1:200, L243), CD86-BV421 (dilution 1:400, IT2.2), CD40-PE
(dilution 1:400, 5C3): all Biolegend, pGSK3ser9-PE (dilution 1:10, REA436, Mil-
tenyi), and BLIMP1-APC (dilution 1:10, 646702, R&D Systems). For intracellular
cytokine detection, cells were restimulated in the final 3 (human) or 5 (mice) hours
of culture with phorbol 12-myristate 13-acetate (50 ng mL−1, Sigma) and iono-
mycin (500 ng mL−1, Sigma) in the presence of Brefeldin A, and GolgiStop (both
1 μl ml−1, both BD Biosciences). For surface staining, cells were harvested and
incubated with Fixable Viability Dye eFluor780 (dilution 1:4000, eBiosciences) for
15 min in phosphate-buffered saline (PBS), followed by the appropriate volume of
antibody diluted in 0.5% bovine serum albumin (BSA) in PBS for 20 min, all at
4 °C. Cells were then washed and fixed in 3% paraformaldehyde (Electron
Microscopy Sciences) for 15 min at room temperature. For intracellular cytokine
staining, cells were incubated with the appropriate volume of antibody, diluted in
0.1% saponin in 0.5% BSA in PBS for 45 min at room temperature or 4 °C over-
night. For staining of transcription factors, or phospho-flow, FoxP3/Transcription
factor buffer set was used, as per manufacturer’s instructions (eBiosciences).
Staining using a secondary antibody against the primary was undertaken either at
room temperature for 1 h, or 4 °C overnight. Cells were acquired using a BD
LSRFortessa or FACSCanto II (BD Biosciences), and analysis conducted using
FlowJo V.10.1 software (Tree Star Inc.).
RNA extraction and qRT-PCR analysis. Harvested cells were lysed in TRIzol
(Ambion, Life Technologies), and stored at −20 °C until RNA extraction by
phenol–chloroform phase separation. Briefly, RNA was eluted by chloroform, and
subsequently precipitated using ice cold isopropanol for 1 h at −20 °C. If necessary,
RNA clean-up was conducted by reprecipitation of RNA in 0.5 volumes of 7.5 M
ammonium acetate, 2.5 volumes 100% ice-cold ethanol, and 1 μl GlycoBlue over-
night at −20 °C. Totally, 40 ng of RNA was added for reverse transcription, using
qPCRBIO cDNA Synthesis Kit (PCR Biosystems) as per manufacturer’s instruc-
tions. qPCR was conducted using 7900HT Fast Real-Time PCR System
(ThermoFisher Scientific). Primers used were: IL10 (Hs00961622_m1), IL6
(Hs00174131_m1), or LTA (Hs04188773_g1), multiplexed with a VIC- labeled 18S
probe (all Thermofisher Scientific) in PCR Biosystems mastermix.
ELISA. Sandwich ELISA was used to detect supernatant analytes. All cell free
supernatants harvested at indicated time points were stored at −20 °C until ana-
lysis. ELISAs for IL-10, IFNγ (both R&D systems, cat nos. DY217B and DY285B,
respectively), TNF (Biolegend, cat no. 430201), or IgM (ThermoFisher Scientific,
cat no. BMS2098) were conducted according to manufacturer’s protocols and
detected on a Victor 1420 multilabel counter (Perkin Elmer) quantifying con-
centrations drawn from a standard curve on each plate.
Western Blotting. Antibodies used were as follows: BLIMP1 (dilution 1:1000,
646702, R&D Systems), pAktser473 (dilution 1:1000, D9E), pERKThr202/Tyr204
(dilution 1:1000, D12.14.4E), and GAPDH (dilution 1:5000, 14C10, all Cell Sig-
naling Technologies). After culture, cells were harvested, washed in ice-cold PBS,
and lysates immediately extracted, or pellets were snap frozen on dry ice for 1 min
and kept at −80 °C until lysis. Whole cell lysates were extracted using RIPA Buffer
(Cell Signaling Technology) with 1× Protease inhibitor cocktail. Lysates were added
to 4× Laemmli Sample Buffer (Bio Rad) with 10% 2-mercaptoethanol, and resolved
on sodium dodecyl sulfate polyacrylamide gel electrophoresis gels, transferred to
polyvinylidene fluoride membranes, blocked (Tris, 5% BSA, 0.05% Tween20) and
probed with the desired antibody. Immunoblots were developed with anti-rabbit-
HRP (Dako) secondary antibody, and proteins visualized by SuperSignal chemi-
luminescent reaction (Pierce) in a ChemiDoc station (BioRad).
siRNA knockdown. siRNA knockdown was conducted by Amaxa nucleofection
using the nucleofector 2b machine, as per manufacturers protocol. siRNA
knockdown was optimized, resulting in the used of 2–3 million cells per condition,
and 500 nM of either BLIMP1 targeted siRNA (Silencer Select assay ID s1992) or
scrambled control (Silencer Select Negative control, both from ThermoFisher
Sceintific). Cells were electroporated using program U-015, resuspended in warm
fully supplemented culture medium, and left to recover for 15 min before stimu-
lation. Knockdown efficiency was determined by western blot at 40 h post
stimulation.
RNA sequencing. CD19+ B cells were stimulated with CpG (1 μM) and IL-2
(25 Uml−1) ± GGTi-298 for 12 h. RNA was isolated by column centrifugation
using RNeasy Plus mini kit (with gDNA removal step) as per manufacturer’s
instructions (Qiagen). Library preparation was completed using NEBNext Ultra
Directional RNA Library Prep Kit for Illumina. Depletion of ribosomal RNA was
performed using Next rRNA Depletion kit (New England BioLabs). RNA quality
was confirmed by bioanalyser (Agilent 2100 Bioanalyzer G2938B), resulting in a
mean RIN score of 8.1, ranging from 7.3 to 8.7. Paired-end sequencing was then
conducted using the HiSeq 2500 platform (Illumina). Raw data were checked for
quality using FASTQC. Processing of the raw data involving alignment (STAR) and
annotation (hg19) were done using Partek. After annotation, TMM-normalized
data were used for downstream statistical analysis using the exact test in the edgeR
package. Inclusion criteria for significantly differentially expressed genes was a false
discovery rate of <0.05 and a fold change of greater than 1.5×. Subsequent pro-
cessing and visualization of the data was completed in RStudio or Morpheus
(Broad Institute, Boston, MA).
Gene set enrichment analysis. Gene set enrichment analysis used on dataset
GSE4355334 was conducted with GSEA v4.0.2 (Broad Institute). Gene expression
data was used from 20 healthy controls (GSM1065214 to GSM1065233) and 8
MKD patients (GSM1065234 to GSM1065241). Gene sets were compared to the
gene set database h.all.v7.0.symbols.gmt [Hallmarks], using 1000 permutations, the
“weighted” enrichment statistic, and “Signal2Noise” for gene ranking.
Statistics. All statistical analysis was conducted using GraphPad Prism v7.0
(GraphPad, San Diego, CA, USA). Paired data were analyzed through either two-
way ANOVA with Dunnett’s test for multiple comparisons, or Freidman’s test with
Dunn’s test for multiple comparisons. Unpaired data were assessed through
ANOVA with Tukey’s test for multiple comparisons. Finally, two-group compar-
ison was performed either through unpaired or paired t test. A P value of <0.05 was
considered statistically significant, and all statistically significant values are shown.
Study approval. Blood samples were obtained locally from healthy donors, and
mevalonate kinase deficient patients were recruited from Royal Free Hospital NHS
Foundation Trust, London, UK or National Human Genome Research Institute/
Inflammatory Disease Section, Bethesda, USA. Written informed consent was
received from all healthy donors and patients used in this study, approved by the
Bromley Research Ethics Committee (REC06/Q0705/20) and by the NIDDK/
NIAMS Institutional Review Board. Animal experiments were performed accord-
ing to the Animals (Scientific Procedures) Act 1986, license PPL 70/7661 and
approved by the Babraham Institute Animal Welfare and Ethics Review Body.
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Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Sequence data generated in this study have been deposited in GEO under the accession
code GSE150245. Publicly available datasets used for analysis are available at GEO under
the accession codes GSE43553 (used in GSEA analysis), and GSE71698 (used for ChIP
and RNA-seq analysis). Source data are provided with this paper.
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